Large Cap
Drug Manufacturers - Specialty & Generic
Stocks Ranked by
Market Capitalization
| Name | Market cap | Price |
Price change % |
|
|---|---|---|---|---|
1
Takeda Pharmaceutical
TAK
$58.6B
| $58.6B | $18.35 | 0.6% |
|
2
Haleon
HLN
$44.8B
| $44.8B | $10.18 | 0.2% |
|
3
Teva Pharmaceuticals
TEVA
$44.4B
| $44.4B | $38.10 | 3.17% |
|
4
Zoetis
ZTS
$31.9B
| $31.9B | $77.29 | 0.16% |
|
5
United Therapeutics
UTHR
$22.2B
| $22.2B | $518.53 | 1.1% |
|
6
Viatris
VTRS
$19.2B
| $19.2B | $16.72 | 1.09% |
|
7
Neurocrine Biosciences
NBIX
$15.6B
| $15.6B | $153.37 | 0.22% |
|
8
Elanco Animal Health
ELAN
$12.5B
| $12.5B | $25.09 | 2.74% |
|
9
Dr. Reddy's Laboratories
RDY
$10.3B
| $10.3B | $12.34 | 0.98% |
|
Large Cap Drug Manufacturers - Specialty & Generic Stocks at a Glance
Specialty and generic drug manufacturers develop branded niche therapies, off-patent generics, and animal-health and cannabis products. Generics compete on price and manufacturing scale, while specialty brands carry pharma-like margins on smaller markets.
There are 9 large cap Drug Manufacturers - Specialty & Generic stocks — companies in the Drug Manufacturers - Specialty & Generic industry with a market cap between $10B and $200B — worth a combined $260B.
The largest by market cap are Takeda Pharmaceutical (TAK) at $58.6B, Haleon (HLN) at $44.8B and Teva Pharmaceuticals (TEVA) at $44.4B.
Among institutional investors, Neurocrine Biosciences (NBIX) drew the most net new fund positions in Q2 2026: 147 funds opened new positions, taking total fund holders up 75 (11%) quarter-over-quarter.
- Combined market cap: $260B across 9 stocks.
- Large Cap: market cap between $10B and $200B.
- Largest constituent: Takeda Pharmaceutical (TAK), $58.6B market cap.
- Most net new fund positions in Q2 2026: Neurocrine Biosciences (NBIX), +75 holders.
Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q2 2026.